Table 4 Characteristics of high and low risk patients for 3-year recurrence free survival and 5-year overall survival
From: [18F]FDG-PET/CT-based risk stratification in women with locally advanced uterine cervical cancer
| Â | 3-year RFS | 5-year OS | ||
|---|---|---|---|---|
High risk (n = 58) | Low risk (n = 125) | High risk (n = 56) | Low risk (n = 127) | |
Age [years] | 49.3 [22.1–82.9] | 55.71 [26.9–87.7] | 50.2 [22.1–82.9] | 55.5 [26.9–87.7] |
MTV [cm3] | 71.0 [12.6-351.9] | 36.1 [3.0-214.7] | 83.8 [12.6-351.9] | 36.1 [3.0-144.4] |
Tumor SUVmax | 19.61 [9.3–60.7] | 14.3 [3.67–29.4] | 18.0 [9.3–60.7] | 14.4 [3.7–51.1] |
[18F]FDG-positive nodes | ||||
No suspicious nodes | 3 (5.2%) | 72 (57.6%) | 4 (7.1%) | 71 (55.9%) |
Pelvic | 15 (25.9%) | 53 (42.4%) | 12 (21.4%) | 56 (44.1%) |
Para-aortic | 32 (55.2%) | 0 | 32 (57.1%) | 0 |
Supraclaviculair | 8 (13.8%) | 0 | 8 (14.3%) | 0 |
FIGO 2009 stage | ||||
IB2 | 9 (15.5%) | 23 (18.4%) | 8 (14.3%) | 24 (18.9%) |
IIA | 4 (6.9%) | 15 (12.0%) | 3 (5.3%) | 16 (12.6%) |
IIB | 16 (27.6%) | 53 (42.4%) | 12 (21.4%) | 57 (44.9%) |
IIIA | 3 (5.2%) | 4 (3.2%) | 4 (7.1%) | 3 (2.4%) |
IIIB | 14 (24.1%) | 25 (20%) | 17 (30.3%) | 22 (17.3%) |
IVA | 6 (10.3%) | 5 (4.0%) | 6 (10.7%) | 5 (3.9%) |
IVB | 6 (10.3%) | 0 | 6 (10.7%) | 0 |
FIGO 2018 stage | ||||
IB2 | 0 | 2 (1.6%) | 0 | 2 (1.6%) |
IB3 | 1 (1.7%) | 6 (4.8%) | 1 (1.8%) | 6 (4.7%) |
IIA | 1 (1.7%) | 9 (7.2%) | 0 | 10 (7.9%) |
IIB | 0 | 34 (27.2%) | 0 | 34 (26.8%) |
IIIA | 0 | 4 (3.2%) | 1 (1.8%) | 3 (2.4%) |
IIIB | 2 (3.4%) | 13 (10.4%) | 3 (5.3%) | 12 (9.4%) |
IIIC1 | 15 (25.9%) | 53 (42.4%) | 12 (21.4%) | 56 (44.1%) |
IIIC2 | 32 (55.2%) | 0 | 32 (57.1%) | 0 |
IVA | 0 | 4 (3.2%) | 0 | 4 (3.1%) |
IVB | 7 (12.1%) | 0 | 7 (12.5%) | 0 |